Introduction
V-Jun was originally discovered as the oncogenic eector of Avian Sarcoma Virus 17 (Maki et al., 1987) . Overexpression of viral Jun induces cell transformation in both avian and mammalian cell culture models (Bos et al., 1990; Castellazzi et al., 1990; SchuÈ tte et al., 1989; Wong et al., 1992) . In chicken embryo ®broblasts (CEF), signi®cant dierences in transforming eciency occur between v-Jun and its cellular counterpart, c-Jun (Bos et al., 1990; Castellazzi et al., 1990; Wong et al., 1992) . Several structure function studies have been undertaken to elucidate the mechanism(s) of Jun induced oncogenic transformation. These studies have demonstrated that these dierences in transformation potential between v-Jun and c-Jun map to structural changes in both coding and noncoding regions (Bos et al., 1990; Morgan et al., 1992 Morgan et al., , 1993 .
Characterization of the structure and function of vJun and its cellular counterpart, c-Jun, has progressed rapidly primarily as a result of early observations which identi®ed it as a transcription factor (Angel et al., 1988; Bohmann et al., 1987; Bos et al., 1988) . Structural analysis has de®ned Jun as a member of the basic leucine zipper (b-zip) family of transcription factors. Functional studies have demonstrated speci®c structural domains responsible for DNA binding, transcriptional activation and dimerization (reviewed in: Ransone and Verma, 1990; Vogt and Bos, 1989; Vogt and Morgan, 1990) .
Although transformation by Jun requires intact dimerization, DNA binding and transcriptional activation structural domains , heterodimerization with other Jun or Fos family members is not required Hartl and Vogt, 1992; Hughes et al., 1992) . In rodent cells, transformation resulting from overexpression of c-Jun has been correlated to increases in DNA binding and transcriptional regulatory activity (SchuÈ tte et al., 1989) . Indeed, mutations which aect either DNA binding or transcriptional activation abolish transforming activity (Alani et al., 1991; Brown et al., 1993; GrangerSchnarr et al., 1992; Lloyd et al., 1991) . These results are in striking contrast to what has been observed in response to Jun induced transformation of avian cells. Overexpression in CEF, of either c-Jun or v-Jun, does not result in measurable increases in any traditional Jun activities (Hadman et al., 1993; Hawker et al., 1993) . Consistent with this observation, mutations in the JNK phosphorylation sites (ser 63 and 73), which have been shown to inhibit Jun transactivation activity in rodent ®broblasts, do not adversely aect oncogenic activity in CEF (Metivier et al., 1993) . In contrast to mammalian cell models, overexpression of c-Jun in avian ®broblasts induces only a weak oncogenic response in cell culture. Thus, in avian cells, a correlation between Jun function and oncogenic potential has not been convincingly demonstrated.
These observations have lead to suspicions that Jun induced transformation of avian cells does not follow the existing paradigm. Although deletion studies have demonstrated that cell transformation requires the general presence of the DNA binding domain , this need may result from speci®c conformational requirements necessary for protein ± protein interactions rather than speci®c DNA binding requirements. In support of this model, Jun is known to indirectly in¯uence the expression of promoters through non AP-1 binding sites as a result of interactions with a variety of non leucine zipper containing transcription factors such as the glucocorticoid receptor (GR), NF-kB, NF-1, MyoD, and NFAT (Bengal et al., 1992; Boise et al., 1993; Kerppola and Curran, 1993; Miner and Yamamoto, 1992; Robinson et al., 1995; SchuÈ le et al., 1990; Stein et al., 1993a,b; Touray et al., 1991; Yang-Yen et al., 1990 . Many of these interactions require the presence of the DNA binding domain but do not necessarily require AP-1 target recognition.
These ®ndings, coupled with the lack of correlation in CEF between AP-1 activity and transforming potential, have lead us to propose two dierent models by which v-Jun may induce cell transformation of CEF. The ®rst model follows the existing paradigm which requires direct binding of v-Jun to AP-1 elements in selected gene targets. The deregulation of these targets serves as a trigger for oncogenic transformation. In the second model, v-Jun deregulates gene targets through an indirect mechanism that does not require direct AP-1 target recognition but functions by in¯uencing gene expression of non AP-1 target genes through protein ± protein interactions with other transcription factors. To distinguish between these models, we have generated and tested the oncogenic potential of several v-Jun DNA binding speci®city mutants.
Results

Construction of v-Jun mutants with altered target specificity
c-Jun belongs to a family of related transcription factors referred to as b-zip proteins. Some members of this class of proteins exhibit similar binding speci®cities whereas others are completely dierent. For instance the yeast transcription factor GCN4 recognizes the same target sequence as c-Jun (TGACTCA) whereas c/ EBP binds a target much removed from this sequence (ATTGCGCAAT) (Johnson, 1993; Suckow et al., 1993) . Mutational studies have demonstrated that the basic region adjacent to the leucine dimerization domain is directly responsible for speci®city of target recognition in this class of proteins. Substitution of a few critical amino acids in the basic region of GCN4 with those found in c/EBP results in a mutant GCN4 protein in which DNA binding speci®city has been altered from TGACTCA (GCN4 target) to ATTGCG-CAAT (c/EBP target) (Johnson, 1993; Suckow et al., 1993) . Mutants such as this have the advantage that they exhibit altered functional speci®city while retaining their structural integrity.
Our goal was to generate active mutant Jun proteins which no longer bind to AP-1 target sequences but rather recognize an unrelated DNA motif. To accomplish this, we used an approach similar to that described above for GCN4 (Figure 1 ). We generated two dierent speci®city mutants. The ®rst, VJCEBP contains eight point mutations in the basic DNA binding domain of v-Jun. The second, VJGLZ/CEBP, contains the same mutations in the backbone of the VJGLZ dimerization mutant (Hughes et al., 1992) . VJGLZ contains the leucine zipper region of GCN4 and as such can not form heterodimers with any endogenous Jun or Fos family members (Hughes et al., 1992) . In addition, VJGLZ has been shown to retain transforming potential (Hughes et al., 1992) . By using this VJGLZ mutant of v-Jun as the backbone, we eliminate potential contributions to DNA binding through heterodimerization with endogenous Jun and Fos proteins and increase our probability of completely eliminating AP-1 DNA binding activity.
We used site directed mutagenesis, by overlapping PCR, to substitute eight speci®c amino acids within the Jun basic DNA binding domain. The structure of these DNA binding mutants, VJCEBP and VJGLZ/CEBP, are shown schematically in Figure 1 . Note that the amino acid changes engineered into these mutants disrupt an antigenic site within the carboxy terminus. Expression of VJCEBP or VJGLZ/CEBP can still be detected with antibodies against amino terminal domains but not with antibodies that recognize this carboxy terminal region. We have utilized this dierence in antigenic speci®city to characterize expression of these mutant proteins.
Characterization of DNA target specificity of VJCEBP and VJGLZ/CEBP
In order to demonstrate a change in DNA binding speci®city we generated v-Jun (VJ-1), VJGLZ, VJCEBP, VJGLZ/CEBP and c-Fos proteins either by in vitro transcription and translation (v-Jun, VJCEBP, c-Fos) or by bacterial expression from the pTrcHis vector (VJGLZ, VJGLZ/CEBP). Expression from the pTrcHis vector generates fusion proteins, containing six histidine residues at the amino terminus, that are easily puri®ed by Nickel chelate anity chromatography. The DNA binding speci®city of these proteins was compared using double-strand oligonucleotides speci®c for AP-1 or c/ (Figure 2 ). These results demonstrate that VJCEBP has the potential to interact with endogenous AP-1 proteins to expand target speci®city. For instance, in this VJCEBP/cFos heterodimer, the c-Fos protein may drive AP-1 target recognition whereas VJCEBP allows binding to c/ EBP sites.
We have previously demonstrated that VJGLZ is restricted to the formation of homodimers and will not dimerize with c-Fos (Hughes et al., 1992) . The DNA binding speci®city of VJGLZ and VJGLZ/CEBP are shown in Figure 3 . As expected, the v-Jun homodimer (VJGLZ) recognizes and binds to the AP-1 consensus sequence but not the c/EBP DNA sequence. The VJGLZ/CEBP mutant, on the other hand, does not bind at all to the AP-1 DNA target. It does however bind speci®cally to the c/EBP consensus sequence. Thus, VJGLZ/CEBP exhibits the predicted change in DNA binding speci®city from AP-1 to c/EBP.
The results from Figures 2 and 3 demonstrate a range of binding speci®cities by these mutants. v-Jun and VJGLZ bind only to AP-1 sites. VJGLZ/CEBP will only bind to c/EBP. VJCEBP will bind c/EBP sites as a homodimer but can also bind to AP-1 sites when heterodimerized with other AP-1 proteins such as cFos. Interestingly, these heterodimers exhibit an expanded target binding speci®city to encompass both AP-1 and c/EBP.
We also tested, by transient cotransfection in CEF, the ability of VJCEBP and VJGLZ/CEBP to activate transcription from a synthetic promoter-reporter carrying a single c/EBP recognition element. Interestingly, no elevation in transactivation was observed with either construct (not shown) suggesting that the v-Jun backbone of these mutants is not conducive to activation from this particular promoter context (see Materials and methods). These results are consistent with our previous observations which demonstrated a lack of transactivation by both v-Jun and c-Jun, in CEF, on a promoter-reporter carrying a single AP-1 element (Hadman et al., 1993) . To accomplish this, we cloned the VJCEBP and VJGLZ/CEBP mutants into the RCAS avian retroviral expression vector and transfected the resulting plasmid into chicken embryo ®broblasts. We then characterized their expression, their eect on in vivo target regulation and their oncogenic potential. Figure 4 we compare, by immunoblot analysis, the expression of v-Jun (V), VJGLZ (G), VJCEBP (E) and VJGLZ/CEBP (G/E) to that of the RCAS vector (R). The mutations in VJCEBP and VJGLZ/CEBP fall within the antigenic site of the carboxy terminal antibody (Oncogene Science c-Jun/AP-1 Ab-1). As predicted, expression of VJCEBP and VJGLZ/CEBP could not be detected with this antibody (Figure 4b ). In contrast, Figure 4a clearly shows high level expression of each of the Jun proteins, including VJCEBP and VJGLZ/CEBP, using an antibody directed against the amino terminus (Santa Cruz Biotechnology c-Jun/AP-1 (N) sc45).
Expression in CEF In
Eect on expression of in vivo targets Our in vitro DNA binding studies presented in Figures 2 and 3 demonstrated a change in target speci®city by the VJCEBP and VJGLZ/CEBP mutants. In order to determine if our mutant would dierentially aect the expression of target genes in vivo, we assayed its eect on deregulation of three known v-Jun associated gene targets: JTAP-1 (Hadman et al., 1996) , apolipoprotein A-1 (JTAP-4) (Hadman et al., 1998) and c-Jun (Hussain et al., 1998) . Both apolipoprotein A-1 and c-Jun are downregulated in response to v-Jun overexpression in CEF whereas JTAP-1 is upregulated. The eect that expression of v-Jun, VJGLZ, VJCEBP, and VJGLZ/CEBP has on these gene targets is presented in Figure 5 . As seen before, v-Jun expression leads to an increase in JTAP-1 and decreases in both apolipoprotein A-1 and c-Jun (Hadman et al., 1996 (Hadman et al., , 1998 Hussain et al., 1998) . Interestingly, the v-Jun homodimer mutant VJGLZ, does not downregulate c-Jun or upregulate JTAP-1 suggesting that regulation of these targets by v-Jun requires heterodimerization with other AP-1 proteins. In contrast, VJGLZ does downregulate apolipoprotein A-1 suggesting that the v-Jun homodimer is sucient for regulating this gene. The eect on expression of these target genes by both of the binding speci®city mutants, VJCEBP and VJGLZ/CEBP, is indistinguishable from the vector infected RCAS control. These results complement our in vitro studies (Figures 2 and 3 ) and demonstrate an in vivo change in target expression as a result of mutational changes that aect the DNA binding speci®city of v-Jun.
Eect on Oncogenic transformation of CEF We used three dierent assays (cell proliferation, focus formation and agar colony growth) to examine the transformation potential of VJCEBP and VJGLZ/ CEBP in our CEF model. Figures 6 and 7 show the results of these dierent assays. As a ®rst measure of oncogenic potential, we measured cell proliferation over a 6 day period as a function of expression of vJun (VJ-1), VJGLZ, VJCEBP, VJGLZ/CEBP or empty vector (RCAS) (Figure 6 ). Our results demonstrate that both v-Jun and VJGLZ proliferate at higher rates than the RCAS control and both of the binding speci®city mutants. The focus forming assay measures release from contact inhibition whereas the soft agar colony assay measures the ability to grow in an anchorage This region plays an important role as a docking site for the JNK family of kinases. In addition, v-Jun has two point mutations leading to two single amino acid changes in the carboxy terminus. One of these changes is a serine to phenylalanine mutation at c-Jun residue 226 which is an important phosphorylation site for glycogen synthase kinase (GSK III). Phosphorylation at this residue has been shown to inhibit DNA binding. The other mutation is a cysteine to serine mutation at v-Jun residue 252. This cysteine residue is important in redox regulation of DNA binding by c-Jun through the interaction with a protein called Ref1 (Abate et al., 1990; . Both of these regulatory sites have been mutated in v-Jun.
We therefore used site directed mutagenesis to create dierent combinations of these two residues in the background of both v-Jun and c-Jun. These dierent mutants are shown schematically in Figure 8a . Six dierent combinations are shown. Wild type v-Jun (VJ-1) contains the phenylalanine and serine mutations (and can therefore be designated VJFS). Wild type cJun (CJ-3) has a serine and a cysteine at these respective positions (CJSC). Each of the other possible combinations are also shown (VJSS, VJFC, CJSS and CJFC). Each of these mutants was cloned into the RCAS expression vector and transfected into CEF. Figure 8b shows representative expression levels of the mutant proteins in CEF. The transformation potential of each of these mutants was tested by focus formation. Representative focus assays are shown in Figure 9 . As seen previously, v-Jun (VJ-1 (VJFS)) is very ecient at forming foci compared with c-Jun (CJ- (Bos et al., 1990) ). The single point mutation CJSS has a clear increase in the number of foci formed compared with CJ-3 (CJSC). Interestingly, the CJFC mutant was just as ecient at focus formation as VJ-1. This demonstrates a single amino acid change in c-Jun can greatly increase its oncogenic potential. Both the VJSS and VJFC mutants were also highly transforming. We assayed each of these mutants for JTAP-1 and apolipoprotein A-1 expression by Northern blot analysis (Figure 10) . Interestingly, JTAP-1 expression did not correlate at all with transformation potential. JTAP-1 levels in RCAS, CJFC and VJFC were all equivalent even though these mutants varied widely in their oncogenic potential. In addition, JTAP-1 expression appeared elevated in CJSS, VJSS and VJ-1 (VJFS) which also varied greatly in their transforming activities. These results are in agreement with our Northern blot data in Figure 5 which showed that the transforming VJGLZ did not induce an elevation in JTAP-1. Downregulation of apolipoprotein A-1 showed a similar lack of correlation with oncogenic activity. High levels of apolipoprotein A-1 were seen in VJFC and CJFC, which were highly transforming ( Figure 9 ). Similar high levels of apolipoprotein A-1 were seen with CJ-3 (CJSC) which exhibits low transforming potential. Other mutants with weak transformation potential such as CJSS show reduced levels of apo A-1 similar to that found with the highly transforming VJ-1 (VJFS). Interestingly, the correlation in expression of both JTAP-1 and apolipoprotein
A-1 appears to be with the cysteine to serine mutation rather than with cell transformation. Each of the mutants with a serine at this residue (CJSS, VJSS) exhibit elevated levels of JTAP-1 in comparison to those with a cysteine at this position (CJFC, VJFC). The same pattern can also be seen for apolipoprotein A-1, although this gene is suppressed.
Discussion
Jun has two de®ned biochemical functions. It can bind speci®cally to DNA sequences found in promoters and enhancers of speci®c genes, and once bound, it can activate or repress transcription. Before Jun can bind DNA, it must ®rst dimerize either with itself or with a heterologous bzip protein such as c-Fos. Speci®c structural domains have been mapped which are responsible for each of these functions. The role of each of these functions in cell transformation is not clear. Although deletion studies have demonstrated a requirement for speci®c structural elements, a correlation with functional activity has not been as straight forward. In rodent cells, overexpression of c-Jun results in cell transformation in vitro and tumor formation in vivo (SchuÈ tte et al., 1989) . Along with overexpression comes an increase in AP-1 speci®c DNA binding and transcriptional regulatory activity ± properties consistent with an oncogenic mechanism utilizing both of these activities. Concordant with this hypothesis, mutations that aect DNA binding or transcriptional activation activity abolish transforming activity (Brown et al., 1993; Granger-Schnarr et al., 1992; Lloyd et al., 1991) . Quite strikingly, a completely dierent eect is seen in avian cells. Overexpression of c-Jun, although weakly transforming in vitro, is not tumorigenic in vivo (Bos et al., 1990; Castellazzi et al., 1990; Wong et al., 1992) . Structural alterations found in v-Jun are required to fully activate c-Jun's oncogenic potential (Bos et al., 1990) . Perhaps more striking is the observation that overexpression of c-Jun or its oncogenic counterpart vJun, in avian cells, does not result in any measurable increase in Jun activity (Hadman et al., 1993; Hawker et al., 1993) . An inverse correlation between AP-1 activity and cell transformation in CEF has lead to the speculation that negatively regulated targets may play an important role in mediating the oncogenic phenotype. The regulatory activity of AP-1 heterodimers however, is not always easy to predict based on DNA binding activity. Many examples exist demonstrating that a speci®c AP-1 heterodimer will activate one promoter while having either no eect or a negative eect on another. Oncogenic transformation is therefore likely to involve both positive and negative regulation of critical target genes.
These observations suggest that Jun induced cell transformation may result from multiple mechanisms. Deletion studies have already demonstrated that cell transformation requires the general presence of the DNA binding domain . This need, however, may result either from speci®c DNA binding requirements or from speci®c conformational requirements necessary for protein ± protein interactions.
Two dierent oncogenic models can be envisioned. In the ®rst model, transformation is dependent on direct binding and deregulation of target genes In this study, we have used the following approach to distinguish between these models. We constructed two v-Jun mutants (VJCEBP and VJGLZ/CEBP) with altered DNA binding speci®city. We demonstrate in Figures 2 and 3 that both of these mutants, as homodimers, lose the ability to bind and recognize an AP-1 target sequence. Interestingly, each of these mutants will recognize the c/EBP target sequence with high anity. The VJCEBP mutant has retained the ability to form heterodimers with AP-1 family proteins. Interestingly, upon heterodimerization, this mutant will bind both AP-1 and c/EBP recognition sites. Consistent with these in vitro studies, regulation of known in vivo v-Jun targets (JTAP-1, apolipoprotein A-1, and cJun) is abolished ( Figure 5 ).
These results demonstrate that VJCEBP and VJGLZ/CEBP have altered binding speci®city both in vitro and in vivo. In order to test the eect of this mutant on oncogenic transformation, we utilized three common assays which measure dierent oncogenic behaviors. Both of the binding speci®city mutants were completely refractory to any form of oncogenic transformation. We therefore conclude that AP-1 binding site recognition is a necessary prerequisite to v-Jun induced transformation of CEF. This provides strong support for the ®rst model in which transformation is dependent on direct binding and deregulation of target genes containing Jun responsive elements.
An important question that remains to be answered concerns the identi®cation of these oncogenically relevant target genes. We and others have identi®ed several targets associated with the v-Jun transformed phenotype (Fu et al., 1999; Goller et al., 1998; Hadman et al., 1996 Hadman et al., , 1998 Hartl and Bister, 1998; Hussain et al., 1998) . As more and more targets are identi®ed, the problem of how to sort out the`important' from the `non important' becomes a tremendous task. One method, is to isolate targets one at a time, perform extensive characterization and then test their biological role as it relates to oncogenic activity. This hit and miss approach is an extremely slow, labor intensive and low yield process. Another way is to exploit dierences in phenotypes of various Jun mutants and correlate speci®c patterns of gene expression with cell transformation. Those genes that consistently associate with transformed phenotypes are logical targets for further biological testing. With this in mind, we created a series of v-Jun and c-Jun mutants that vary by single amino acid changes in important regulatory regions.
We then compared the transformation potential of wild type v-Jun and c-Jun with these four point mutants (VJSS, CJSS, VJFC and CJFC) and correlated this with expression levels of two of our target genes, JTAP-1 and apolipoprotein A-1. Using these mutants, we found a striking lack of correlation of either of these target genes with cell transformation as measured by focus formation. These results demonstrate the power of this approach as a screening tool for the identi®cation of oncogenically relevant gene targets.
Although JTAP-1 and apolipoprotein A-1 deregulation did not correlate with cell transformation, we did ®nd an interesting correlation with a structural component of our functional mutants. Only the Jun proteins with a single amino acid change at c-Jun position 252 from cysteine to serine were able to upregulate JTAP-1 or downregulate apolipoprotein A-1. This amino acid residue (cys) is known to regulate Jun function through an oxidation reduction mechanism which involves interaction with the Ref1 protein (Abate et al., 1990; . When reduced, DNA binding activity of Jun is stimulated. Mutation of this cysteine to a serine uncouples the Jun protein from this regulation. Our results indicate that this uncoupling has important functional consequences for target gene regulation.
We can draw two important conclusions from the studies presented here. The ®rst is that, despite the lack of correlation between AP-1 function and cell transformation in CEF, speci®c AP-1 target recognition is prerequisite to v-Jun induced oncogenic activity. This supports the model by which direct activation of oncogenic gene targets by v-Jun results in a cascade of events eventually leading to cell transformation. The second is that the functional signi®cance of v-Jun associated gene targets, with respect to cell transformation, can be dissociated by screening their expression in response to a series of mutant Jun proteins. This brings us a step closer to the future challenge of identifying the relevant oncogenic gene targets of the v-Jun oncoprotein.
Materials and methods
Mutagenesis of the v-Jun DNA binding domain
Two step overlapping PCR was used to substitute amino acids within the basic DNA binding region of VJ-1 and VJGLZ with those predicted to be involved in target speci®city of c/EBP. Initially, two independent PCR reactions were performed with primer pairs A1/C1 and B1/C2 using pA VJGLZ (Hughes et al., 1992) as template. Primer A1 is: 5'-ACGAGTTTGCACAGCGAG-3'; Primer B1 is: 5'-CTGTTGTGTTAGCATTAGCT-3'; Primer C1 is: 5'-CCGGCTTTTGCGCACCGCAATATTGTTTCTCTCGCG-TCGTACCCGGTATTTGATTCTCTCCTGCG-3'; Primer C2 is: 5'-CGCAGGAGAGAATCAAATACCGGGTACGACG-CGAGAGAAACAATATTGCGGTGCGCAAAAGCCGG-3'.
Primers C1 and C2 represent complementary mutagenic primers containing the directed amino acid changes in the basic DNA binding domain as well as a novel Ssp1 restriction site. Primers A1 and B1 are directed against Jun sequences upstream and downstream of the BstXI and A¯II restriction sites in VJGLZ (Hughes et al., 1992) . PCR reactions were carried out with Gibco-BRL Vent DNA polymerase in 16buer containing 1.1 mM MgCl 2 using 1 ng of template DNA. Two PCR cycles of 948C 1 min, 378C 1 min, 728C 30 s; followed by 33 cycles of 948C 30 s, 558C 30 s, 728C 30 s and one ®nal extension at 728C for 7 min were performed. This resulted in the ampli®cation of fragments of 130 and 151 bp with primer pairs A1/C1 and B1/C2 respectively. Approximately 1 ng of gel puri®ed fragments A1/C1 and B1/C2 were used as template in a secondary PCR with primers A1 and B1. This PCR reaction was performed with Gibco-BRL Taq DNA polymerase in 16Promega buer containing 1.1 mM MgCl 2 using the same cycling conditions described above. The resulting PCR ampli®ed fragment of 281 bp was digested with A¯II and BstXI, gel puri®ed from low melt agarose, and then ligated to the similarly digested pA VJGLZ creating pA VJGLZ/CEBP. This mutation was con®rmed by digestion with Ssp1 and DNA sequencing. pA VJCEBP was constructed in an identical manner using pA VJ-1 (Bos et al., 1990) as template.
Construction of expression plasmids
Expression plasmids containing v-Jun (VJ-1) and VJGLZ have been previously described (Bos et al., 1990; Hughes et al., 1992) . RCAS VJGLZ/CEBP and RCAS VJCEBP were constructed by ligating the Cla 1 fragment of pA VJGLZ/ CEBP and pA VJCEBP respectively into the ClaI site of the avian retroviral expression vector, RCAS (Hughes and Kosik, 1984; Hughes et al., 1987) . The pTrcHis VJGLZ expression plasmid has been previously described (Hughes et al., 1992) . pTrcHis VJGLZ/CEBP was constructed by insertion of the EcoRI to BamHI fragment of pG VJGLZ/ CEBP into the EcoRI BamHI digested pTrcHisB vector (Invitrogen). pG VJGLZ/CEBP was constructed by inserting the ClaI fragment from pA VJGLZ/CEBP into ClaI digested pGEM7z (Promega). Expression and puri®cation of fusion proteins was done as previously described (Hughes et al., 1992) . pG VJCEBP was constructed by inserting the ClaI fragment of pA VJCEBP into ClaI digested pGEM7z. Expression was monitored by Western blot analysis or in vitro transcription and translation.
Construction of v-Jun and c-Jun point mutants (VJSS, VJFC, CJSS, CJFC)
The point mutant v-Jun and c-Jun clones were constructed by overlapping PCR essentially as described above for the DNA binding mutants. The VJSS, CJSS, VJFC and CJFC mutants were generated using the following primers and CJ-3 DNA as template. Primer C: Jun 763 ± 789 -CCTCCCCTGTtCCCgATcGACATGGAG; Primer C': Jun 789 ± 763 -CTCCATGTCGATCGGGaACAGGGGAGG; Primer D: Jun 837 ± 868 -GCGGCtTCgAAATcCCGGAAAAGGAAGTTGG; Primer D': Jun 868 ± 837 ± CCAACTTCCTTTTCCGGgATTTcGAaGCCGC; Primer E: Jun 463 ± 480 ± ACGAGTTTG-CACAGCGAG; Primer F: Jun 930 ± 911 ± CTGTTGTGT-TAGCATTAGCT.
Mutant CJSS was constructed with primer pairs E to D', D to F followed by E to F. The PCR product was cleaved with BstXI and A¯II and cloned into the similarly cut backbone of pAVJ-1 to create pAVJSS or pACJ-3 to create pACJSS. Cloning into RCAS was performed as described above. Mutant CJFC was constructed with primer pairs E to C', D to C followed by E to F. The BstXI to A¯II PCR product was cloned to generate pAVJFC and pACJFC as described above. Each of these mutants was sequenced to ensure that the appropriate mutation had been generated.
Cell culture and transformation assays
Chicken embryo ®broblasts were prepared from 10 day old embryos as described previously (Bos et al., 1990) . RCAS plasmids were transfected into CEF using the DMSO polybrene method (Kawai and Nishizawa, 1984) . Focus and soft agar colony assays were performed as previously described (Bos et al., 1990) . Cell proliferation assays were performed using the Promega Cell Titer 96 Non-Radioactive Cell Proliferation Assay as described by the manufacturer. Expression of Jun proteins was monitored by immunoblot analysis using antibodies directed against the amino (Santa Cruz Biotechnology c-Jun/AP-1 (N) sc45) and carboxy terminus (Oncogene Science c-Jun/AP-1 Ab-1). Northern blots were performed as previously described (Hadman et al., 1996) using total RNA isolated from various mutant Jun expressing CEF by lysis in guanidinium isothiocyanate. The JTAP-1 and apolipoprotein A-1 probes have been previously described (Hadman et al., 1996 (Hadman et al., , 1998 . Endogenous c-Jun was detected using an MluI to EcoRI fragment of pGCJ-1 as a probe. This fragment represents the 3' untranslated region of chicken c-Jun which is absent in all of the dierent c-Jun and v-Jun expression plasmids.
Mobility shift assays
Gel shift assays were performed using either in vitro transcribed and translated protein (c-Fos, v-Jun (VJ-1), VJCEBP) or bacterial expressed and puri®ed VJGLZ and VJGLZ/CEBP generated from the pTrcHis expression plasmids described above. The double-stranded AP-1 and c/ EBP DNA binding sites were purchased from Santa Cruz Biotechnology. The AP-1 sequence is: 5'-CGCTTGAT-GACTCAGCCGGAA-3'. The c/EBP sequence is: 5'-TGCA-GATTGCGCAATCTGCA-3'. Double-strand oligos were labeled with g-32 P-ATP. Competitions were done with a 50-fold molar excess of unlabeled probe. Polylinker from pGEM 4, PCR ampli®ed between SP-6 and T7 as described previously (Hadman et al., 1993) , was used as an additional non-speci®c competitor.
Construction and assay of promoter-reporter plasmids
In order to generate a promoter reporter with a single c/EBP recognition element, the plasmid pMCAT (Seto et al., 1990) was digested with the restriction enzyme BglII followed by calf intestinal phosphatase (Gibco) treatment. An oligonucleotide carrying a single c/EBP recognition element and its complement (5'-TGATAGGATCCTGCAGATTGCGCAAT-CTGCAGGATCCATAGT-3'), were boiled for 3 min and allowed to slowly cool to room temperature to allow for annealing. This fragment was then digested with BamHI and gel puri®ed. The BglII linearized pMCAT plasmid was ligated with the BamHI digested synthetic oligo containing a single CEBP consensus binding site and transformed into E. coli competent cells. Positive clones were isolated and digested to verify that they contained an insert of the expected size. These positive clones were then sequenced to verify orientation and sequence of the insert. The resulting construct is referred to as snglCEBP-CAT.
Co-transfections of Jun mutant plasmids with promoter/reporter constructs
Transfection of CEFs were conducted either by the DMSOpolybrene procedure (Kawai and Nishizawa, 1984) or by using Fugene reagent (Boehringer Manheim) following the manufacturers protocol. Fugene transfections were conducted using 3 ug of DNA (1.5 ug/each plasmid) and 6 ul of Fugene reagent. DMSO transfections were conducted utilizing 2 ug of DNA (1 ug/each plasmid). CEF's were seeded at a density of 1610 6 cells/60 mm tissue culture plate. Protein was harvested at 48 h post-transfection and quantitated for subsequent assays. CAT assays were done in triplicate as described previously (Hadman et al., 1993) .
